Paul McQuade of Greenberg Traurig, LLP shares some legal aspects of federal technology investment and their potential impact on intended markets.


View Slide Deck

Dr. Todd Haim of the National Cancer Institute SBIR Development Center describes the NCI’s SBIR and STTR programs, their structure, the Institute’s funding interests, and FAQs.


View Slide Deck

Dr. Meg Mooney of the National Cancer Institute discusses new initiatives to accelerate development of cancer therapies in the era of precision medicine.


View Slide Deck

Mr. Henry Ahn of the National Science Foundation speaks on the NSF’s SBIR and STTR programs.


View Slide Deck

The largest-ever gathering in the Australian life sciences!

International BioFest 2016 will be the largest-ever gathering in Australian life sciences, with three major conferences coming together in one week in one place as one integrated network. The event will be held from 24-27 October 2016 in Melbourne by AusBiotech.

Conferences include the 17th International Biotechnology Symposium (IBS 2016), presenting the most advanced topics in biotechnology, green chemistry and its related fields; AusBiotech 2016, Australia’s national life science conference; and Australia Biotech Invest, Australia’s life science investment showcase.

Delegates from the biotechnology, biopharmaceutical, life sciences, business, investment, research, academic and health sectors will gather to celebrate Australian and international life sciences and highlight Melbourne as one of the world’s great biotechnology hubs.


Register now                                                                               Find out more


FreeMind Group to discuss alternative funding

Ayal Ronen, Vice President, FreeMind Group, will be part of the panel discussing alternative funding, discussing how this flexible funding model can be used within the life science sector. Mr Ronen will be joined by Bill Best, Managing Director, On Market Book Builds, and Ross Curtin, CEO, WealthSpring International Group.

View the program

The FreeMind Group is proud to support the upcoming Trans-Pacific Health Science Dialogue!

Where: Boston, MA

When: September 28-29, 2016


Big Players Are Making Big Bets on Biopharma in Asia

  • Chinese investors representing more than $5.5B are looking for Trans-Pacific investments
  • Pfizer is investing $150M in a biologics plant in China
  • BMS expects Opdivo sales in Japan to exceed $1B
  • The Hangzhou Economic Development Area is investing $350M in a global biotech center

Can You Afford to Sit on the Sidelines?

The time to think about establishing, expanding or accelerating an Asian strategy is now. With a lineup of top Asia experts, the Trans-Pacific Health Sciences Dialogue will provide you with a solid grasp of Asian biopharma opportunities and today’s best strategies for market entry and growth. This two-day event provides critical insights you will not find at any other meeting.



For complete details and to register go to:

The FreeMind Group is a proud supporter of AdvaMed 2016

Where: Minneapolis, MN

When: October 17-19, 2016


AdvaMed 2016 is the leading MedTech Conference in North America, bringing more than 1,000 companies together for business development, capital formation, world-class educational opportunities and networking. A “must attend” event featuring a diverse attendee list that includes influential policy-makers, executives and media, AdvaMed 2016 seeks to advance the industry from key perspectives through panel sessions, executive forums and more.

Learn more about the event at


FreeMind is proud to support RESI Boston 2016 and invites you to use discount code FREEMIND100 for $100 off registration!

WhenTuesday, September 13, 2016

Where: The Westin Copley Place, Boston, MA

The first Redefining Early Stage Investments (RESI) Conference took place on September 16, 2013, and three years later, following highly successful events in San Francisco, Houston and Toronto, RESI will return to Boston for the 10th RESI Conference. Life Science Nation (LSN) will be hosting the RESI Boston conference in collaboration with Johnson & Johnson Innovation, JLABS on September 13th, 2016.
RESI Boston is a venue for entrepreneurs to meet with 10 categories of investors that LSN tracks including: Family Offices, Corporate Venture Funds, Angel Groups, Venture Philanthropy, Venture Capital and more. Through the RESI Partnering system, fundraising executives can have up to 16 scheduled meetings as well as many more ad-hoc meetings with diverse life science investors who fit their company’s technology sector, indication and stage of development.